Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00436072 · ClinicalTrials.gov registry record · Phase 1
ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00436072 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 46 participants.
The verdict
NCT00436072, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This research study will test the safety of the investigational drug, ZD6474, in combination with 2 other drugs that are standard in the treatment of colon and rectal cancer (cetuximab and irinotecan). ZD6474 blocks the action of two substances in the body: vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR). VEGFR stimulates the formation of new blood vessels. When cancer cells produce VEGFR, new blood vessels are made that provide blood to the cancer cells. The blood carries nutrients and oxygen, allowing the cancer cells to live and grow. EGFR controls how quickly cells grow and multiply. Both of these substances are found on normal cells, but they are found in much higher levels on cancer cells.
Interventions
- DRUG Cetuximab
- DRUG Irinotecan
- DRUG ZD6474
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2007-02 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00436072
The ClinicalTrials.gov registry entry for NCT00436072 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cetuximab is the first listed.
NCT00436072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00436072 about?
NCT00436072 is a clinical study titled "ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer". This research study will test the safety of the investigational drug, ZD6474, in combination with 2 other drugs that are standard in the treatment of colon and rectal cancer (cetuximab and irinotecan). ZD6474 blocks the action of two substances in the body: vascular endothelial growth factor recepto...
What is the current status of trial NCT00436072?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2007-02. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00436072?
The interventions under investigation include: Cetuximab (DRUG), Irinotecan (DRUG), ZD6474 (DRUG).
Who is sponsoring clinical trial NCT00436072?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.